Why did CONMED (CNMD) stock move recently?

On 7/27/2026, CONMED moved +5.4% — No clear company-specific catalyst found in filings or credible coverage; the stock moved with the broader market or sector ahead of its July 29 earnings report. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is CONMED (CNMD) overvalued or fairly valued?

MarketChacha shows CONMED's valuation in context — a trailing P/E of about 28.2, a forward P/E of about 10.3, a price-to-book of about 1.4 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does CONMED's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.90×) from reported figures — education, not a rating.

What is CONMED's revenue?

CONMED reported revenue of $1.4B for FY2025, with net profit of $47.1M, per official filings.

What is the share price of CONMED (CNMD)?

CONMED last traded at $49.12 (-1.5% on the day), as of 9/1/2026 — a delayed quote shown for education, not investment advice.

CONMED

CNMD · NYSE · Healthcare · United States

Snapshot

TickerCNMD

ExchangeNYSE

SectorHealthcare

IndustryMedical Devices

CountryUnited States

Employees3,900

HeadquartersLargo, United States

Websitewww.conmed.com

Filings tracked20

About CONMED

CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as supporting products include powered resection instruments , fluid management, and visualization systems and the related single-use products that enable surgeons to perform minimally invasive sports medicine surgeries. It also provides battery-powered, autoclavable, large, and small bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under the Hall surgical brand name. In addition, the company offers general surgery products, such as clinical insufflation systems under the AirSeal brand; smoke removal devices under the Buffalo Filter brand; endomechanical products, including the Anchor1 line of tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors, used in minimally invasive surgeries; and electrosurgical solution comprise monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems, and other accessories. Further, it provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products to treat diseases of dilation, hemostasis, biliary, stricture management, infection prevention, and patient monitoring include ECG electrodes, EEG electrodes, and cardiac defibrillation pads. It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. The company was incorporated in 1970 and is headquartered in Largo, Florida.

Who owns it

Insiders0.4%
Institutions99.6%
Public & other0.0%

345 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.16.10%
Earnest Partners LLC8.36%
Vanguard Portfolio Management LLC7.31%
Fuller & Thaler Asset Management Inc.5.27%
State Street Corporation4.73%
Vanguard Capital Management LLC4.53%
Bank of America Corporation4.48%
Dimensional Fund Advisors LP4.40%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Latest ROE of 4.6% is on the low side — the business earns a modest return on shareholder capital.

Cash conversion1.90×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend5.2% → 3.4%

Margin has held broadly steady over the period — stable profitability.

Return on equity4.6%

Latest ROE of 4.6% is on the low side — the business earns a modest return on shareholder capital.

Growth qualityrev 5% · PAT -15%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $369.0M · EPS 1.27

Est. earnings growth -11.5%

Next fiscal year

Rev $1.4B · EPS 4.78

Est. earnings growth +5.4%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$1.4B

Net margin

3.4%

ROE

4.6%

Revenue CAGR (2y)

+5.1%

Profit CAGR (2y)

-14.6%

EPS (FY2025)

1.51

Net profit (FY2025)

$47.1M

Ask MarketChacha about CNMD

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Jul 27, 2026
No clear company-specific catalyst found in filings or credible coverage; the stock moved with the broader market or sector ahead of its July 29 earnings report.
· confidence: low
Jul 24, 2026
CONMED shares rose on continued momentum from reports that the company is exploring a potential sale or strategic alternatives after receiving private equity takeover interest.
source 1 ↗source 2 ↗source 3 ↗· confidence: medium

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$1.4B	$47.1M	1.51	3.4%	4.6%
FY2024	$1.3B	$132.4M	4.25	10.1%	13.8%
FY2023	$1.2B	$64.5M	2.04	5.2%	7.7%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$343.5M	$23.1M	0.77	6.7%
2025Q3	$337.9M	$2.9M	0.09	0.8%
2025Q2	$342.3M	$21.4M	0.69	6.3%
2025Q1	$321.3M	$6.0M	0.19	1.9%
2024Q3	$316.7M	$49.0M	1.57	15.5%
2024Q2	$332.1M	$30.0M	0.96	9.0%
2024Q1	$312.3M	$19.7M	0.63	6.3%
2023Q3	$304.6M	$15.8M	0.50	5.2%
2023Q2	$317.7M	$13.7M	0.43	4.3%
2023Q1	$295.5M	$1.8M	0.06	0.6%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Results of operations, Exhibits
SEC7/29/2026material
10-Q filing
SEC7/29/2026
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC6/17/2026material
8-K — Material agreement, Exhibits
SEC6/4/2026material
8-K — Material agreement, Material financial obligation, Exhibits
SEC6/1/2026material
8-K — Executive/director change, Bylaw/charter change, Shareholder vote results, Exhibits
SEC5/20/2026material
10-Q filing
SEC4/30/2026
8-K — Results of operations, Exhibits
SEC4/29/2026material
8-K — Executive/director change
SEC3/13/2026material
10-K filing
SEC2/17/2026
8-K — Results of operations, Exhibits
SEC1/28/2026material
8-K — Reg FD disclosure, Exhibits
SEC1/12/2026material
8-K — Executive/director change, Exhibits
SEC1/8/2026material

2025

8-K — Reg FD disclosure, Exhibits
SEC12/5/2025material
10-Q filing
SEC11/6/2025
8-K — Results of operations, Exhibits
SEC11/5/2025material
8-K — Executive/director change, Exhibits
SEC9/9/2025material
8-K — Other events
SEC8/8/2025material
10-Q filing
SEC7/31/2025
8-K — Results of operations, Exhibits
SEC7/30/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.